By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More
Synthetic approaches to rational drug design - A changing landscape By Dr Shubh Sharma and Dr Carl Spana It is becoming clearer that newer synthetic approaches for rational drug design may hold the promise of taking us closer to industrialising drug discovery while, at the same time, overcoming the bottleneck… Read More
The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components, and the… Read More
Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More
The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More
RNA interference - A technology platform for target validation, drug discovery and therapeutic development By Dr Krishnarao Appasani In the post genomic era, elucidation of the physiological function of genes has become a major rate-limiting step in the quest to develop 'gene-based-drugs'. As we advance in the 'functional omics' arena… Read More
New developments in antigen-specific immunotherapies By Dr Jorg Schneider and Professor Andrew J. McMichael Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer. Vaccination has been used effectively for more than 200 years to protect individuals from a range of infectious diseases such as polio… Read More
Surface Plasmon Resonance's impact on drug discovery - resolution, throughput and versatility By Dr David G. Myszka and Dr Rebecca L. Rich Surface plasmon resonance (SPR) biosensors have rapidly become a standard tool within the pharmaceutical and biotechnology industries. Label-free, real-time measurements are the calling card for this technology, which… Read More
The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will the zebrafish have… Read More
TRANSCRIPTOMICS - Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or… Read More
A business model for sustainable, strategic relationships By Dr Douglas J. Squires and Dr James E. McClurg Historically relationships between CROs and pharmaceutical and biotech companies, and the results of these relationships, have not met shared expectations for strategic value exchange. This article presents a business model for achieving a… Read More
Second-Generation Protein Drugs By Dr Jeffrey C.Way The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology. This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs are expiring, will second generation proteins,… Read More
New Visions in Ophthalmic Drug Development By Dr Benjamin R. Yerxa, Dr Ward M. Peterson and Robin S.Whitsell Over the last 10 years we have seen the introduction of several new 'ophthalmology only' pharmaceutical products emerge such as Trusopt (dorzolamide, Merck) and Xalatan (latanoprost, Pharmacia). Innovative products such as these… Read More
Better drugs by MICROARRAY By Dr Mark Schena Microarray analysis allows the elucidation of biological processes and pathways on a genomic scale. This revolutionary technology promises an unprecedented view of drug action and side reaction, the ability to identify drug targets and optimise lead compounds, the capacity to predict patient… Read More
The New Blockbuster Drugs - Healthcare packages for particular disease pathologies By Dr Nick Davies and Dr Steve Arlington With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in which it… Read More
Share Share Tweet Email Stem Cell PHARMACEUTICS Stem Cell PHARMACEUTICS By Dr Gregory G. Lennon Recent research advances in the understanding of stem cell properties are inevitably leading to therapeutic strategies potentially applicable to many diseases. The pharmaceutical manipulation of multipotential cells such as stem cells is therefore now primed… Read More